MOLECULAR CYTOGENETICS OF SOLID TUMORS

实体瘤的分子细胞遗传学

• 批准号: 3085860
• 负责人: JONATHAN Alfred FLETCHER
• 金额: $ 6.47万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-08-01 至 1995-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3085860
• 关键词: basal cell carcinoma; cytogenetics; health science research; health science research support; neoplasm /cancer genetics

This physician-Scientist Award will enable Dr. Fletcher to acquire a broad and thorough training in the fields of experimental cytogenetics and molecular biology. In each phase of the award, these skills will be applied to specific research questions in the field of oncology. Phase I will be conducted under the co-sponsorship of Drs. Cynthia C. Morton and Philip Leder, in the Department of Pathology and Genetics, respectively, at Harvard Medial School. A primary focus of this phase will be to localize the causative gene for nevoid basal cell carcinoma syndrome. During Phase I, Dr. Fletcher will also participate in seminars and courses at Harvard Medical School and at the Jackson Laboratory, and will continue extensive work-in-progress on solid tumor cytogenetics. The solid tumor cytogenetics projects will include: 1) identification of characteristic chromosome rearrangements in specific malignancies; 2) investigation of the diagnostic significance of specific cytogenetic patterns in mesenchymal tumors; and 3) determination of the extent and role of genetic instability in adult malignancies. Dr. Samuel E. Lux, Chief of the Hematology-Oncology Division at The Children's Hospital, Boston, and Dr. STeven J. Burakoff, Chief, Division of Pediatric Oncology, Dana-Fraber Cancer Institute, will co-sponsor Phase II of this award. During Phase II, Dr. Fletcher will establish a laboratory devoted to the cytogenetic and molecular characterization of solid tumors at the Dana-Farber Cancer Institute. This laboratory will utilize cytogenetic findings as a basis for subsequent molecular investigations into the etiologies of solid tumors.

该医师科学家奖将使弗莱彻博士获得广泛的 以及实验细胞遗传学领域的全面培训 分子生物学。 在奖项的每个阶段，这些技能将被 应用于肿瘤学领域的具体研究问题。 第一阶段 将在博士的共同赞助下进行。辛西娅·C·莫顿和 Philip Leder，分别在病理学和遗传学系， 哈佛医学院。 此阶段的主要重点是本地化 痣基底细胞癌综合征的致病基因。 阶段期间 我，弗莱彻博士也将参加哈佛大学的研讨会和课程 医学院和杰克逊实验室，并将继续广泛 实体瘤细胞遗传学研究正在进行中。 实体瘤细胞遗传学 项目将包括：1）特征染色体的鉴定 特定恶性肿瘤中的重排； 2) 诊断调查 间充质肿瘤中特定细胞遗传学模式的意义；和 3) 确定成人遗传不稳定性的程度和作用 恶性肿瘤。 Samuel E. Lux 博士，血液肿瘤科主任 波士顿儿童医院，STeven J. Burakoff 博士，科长 儿科肿瘤学、达纳-弗雷伯癌症研究所将共同赞助第二阶段 的这个奖项。 在第二阶段，弗莱彻博士将建立一个实验室 致力于实体瘤的细胞遗传学和分子表征 在达纳法伯癌症研究所。 该实验室将利用 细胞遗传学发现作为后续分子研究的基础 深入了解实体瘤的病因学。